Cellectar Biosciences Inc (NASDAQ:CLRB) has a beta value of 1.01 and has seen 0.58 million shares traded in the recent trading session. The company, currently valued at $15.26M, closed the recent trade at $0.33 per share which meant it gained $0.02 on the day or 5.48% during that session. The CLRB stock price is -1248.48% off its 52-week high price of $4.45 and 33.33% above the 52-week low of $0.22.
The consensus among analysts is that Cellectar Biosciences Inc (CLRB) is Buy stock at the moment, with a recommendation rating of 1.50. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.35.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Sporting 5.48% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CLRB stock price touched $0.33 or saw a rise of 2.91%. Year-to-date, Cellectar Biosciences Inc shares have moved 10.80%, while the 5-day performance has seen it change 15.03%. Over the past 30 days, the shares of Cellectar Biosciences Inc (NASDAQ:CLRB) have changed 36.06%.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 97.25% from the levels at last check today. The projected low price target is $12.0 while the price target rests at a high of $12.0. In that case, then, we find that the latest price level in today’s session is -3536.36% off the targeted high while a plunge would see the stock gain -3536.36% from the levels at last check today.
Cellectar Biosciences Inc (CLRB) estimates and forecasts
The company’s shares have lost -83.68% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 41.77% over the past 5 years. Earnings growth for 2025 is a modest 48.15% while over the next 5 years, the company’s earnings are expected to increase by 32.07%.
CLRB Dividends
Cellectar Biosciences Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024, the former fund manager holds about 2.33% shares in the company for having 1.07 shares of worth $0.35 million while later fund manager owns 568.75 shares of worth $0.19 million as of Sep 30, 2024, which makes it owner of about 1.23% of company’s outstanding stock.
